Liver
You can be slim and still have a fatty liver
A normal weight, a normal check-up and a liver quietly filling with fat. In pooled Indian studies, 38.6% of adults have it — and the thin ones are not spared.
There is a particular kind of Indian patient who is told, every year, that everything is fine. The weighing scale is fine. The blood pressure is fine. There is no pain anywhere. And the liver is filling with fat.
That is about one adult in three. A separate screening of 7,764 Indian adults across 27 cities — a workplace cohort, not a random sample of the country — found an age-adjusted 38.9% [2]. Two different methods, two different decades of data collection, landing in the same place.
First, the name changed
You will still hear NAFLD — non-alcoholic fatty liver disease. The international definition was replaced in 2023 by MASLD: metabolic dysfunction-associated steatotic liver disease. India's own liver society, INASL, formally adopted the new name over its 2023 guidance [9].
The change is not cosmetic. The old name defined the disease by what it was not (alcohol). The new one defines it by what it is: fat in the liver arriving alongside a metabolic problem — blood sugar, blood pressure, waist, triglycerides. In a clinic, ask for whichever word gets you understood. On a report, they mean the same organ.
Slim does not mean safe
This is the part that catches people, and it is the reason the Short exists.
In the DiaFib-Liver study, 9,202 Indian adults with type 2 diabetes — none of them there because of a liver complaint — had their livers scanned with elastography between January and July 2024. Among the 3,996 who were not obese (BMI under 25), 752 had significant liver fibrosis. That is 19%, roughly one in five, in the thin group [4].
And it starts young. A 2025 study scanned 688 medical students in Belagavi, south India, average age 20.5, none of them significant drinkers: 23.1% already had fat in the liver [3].
The mechanism has a name that Indian researchers use without embarrassment: the thin-fat phenotype. Less room for fat under the skin means the overflow goes inward — around the organs, into the liver and the pancreas — at a body weight that looks entirely normal on a scale [8]. Lean MASLD is estimated to make up 10–20% of cases, though that figure is a global one, not an Indian measurement [8].
The scale weighs what is under your skin. It has nothing to say about what is inside your liver.
Why it never hurts
Fat can pack a liver for years and produce no symptom at all, and there is an anatomical reason for it. The working tissue of the liver — the parenchyma — has no pain nerve endings. There is nothing in there to hurt.
What is innervated is Glisson's capsule, the sheath around the outside. If the liver swells enough to stretch that capsule, you can get a dull ache under the right ribs. So this is not "a fatty liver never hurts". It is: the fat itself is painless, and by the time anything aches, the organ has already had to change size.
Which is why lean MASLD is usually found by accident, on a scan or a blood test ordered for something else [8].
What it can turn into
Fat alone is not the danger. Scarring is.
In the same 9,202 Indian adults with type 2 diabetes [4]:
- 26% (2,433 of 9,202) had clinically significant fibrosis
- 14% (1,289 of 9,202) had advanced fibrosis
- 5% (491 of 9,202) were in the probable-cirrhosis range — and none of them had come in with liver symptoms
Two words of care on that last line, because they matter. Probable cirrhosis: elastography is a stiffness reading, not a biopsy. And every one of those percentages belongs to its own denominator — quote them with the denominator or not at all.
The most uncomfortable finding in that study is easy to miss. Among 2,847 patients with no detectable liver fat, 13% (370) already had clinically significant fibrosis, and 4% (107) were in the probable-cirrhosis range [4]. A clean fat reading is not a clean liver.
If you have type 2 diabetes, the background risk is higher still: pooling 18 Indian studies covering 81,364 adults with diabetes, 56.9% had fatty liver [5].
What actually shifts it
Here is where Indian trials have been unusually useful, and unusually unglamorous.
A randomised trial at PGIMER Chandigarh took 66 non-obese Indian adults with MASLD and raised ALT. Lifestyle change alone significantly reduced liver fat over six months — a median fall of 14 dB/m on the scan's fat measure. Adding a drug to it produced a fall of 24 dB/m, which sounds better until you read the statistics: p = 0.52. The difference was not significant [6].
The drug arm did win on three secondary measures — insulin resistance, triglycerides and ALT — so this is not "the drug does nothing". It is: on liver fat and fibrosis, the drug did not beat lifestyle alone.
A second Indian trial, 150 non-diabetic adults aged 19–55 at BHU Varanasi, compared saroglitazar and vitamin E against lifestyle over 24 weeks and found neither better than lifestyle on liver stiffness or fibrosis score [7].
Two trials, two Indian centres, the same answer. The thing that works is the thing nobody can sell you.
What to actually do about it
These are the questions worth taking into the room:
- Ask what your liver looks like, not just what your weight is. A normal BMI does not exclude this, and neither does feeling well.
- If you have type 2 diabetes, ask specifically about fibrosis, not only about fat. The fibrosis can be there without the fat [4].
- Treat the metabolic problem, because that is what the new name is pointing at: sugar, waist, triglycerides, blood pressure.
- Do not start a supplement or a liver drug on your own. In the Indian trials, the additions did not beat the boring part.
Sources
Every figure above, with the population it describes and the years the data covers. Indian data first, newest evidence first.
- Shalimar, Elhence A, Bansal B, et al. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. J Clin Exp Hepatol 2022;12(3):818–829. 23,581 Indian adults pooled from 62 datasets in 50 studies; literature to April 2021. 38.6% (95% CI 32–45.5). Subgroups, never mixed with the headline: average-risk 28.1%, high-risk 52.8%, community-based 28.2%, children 35.4%.
https://doi.org/10.1016/j.jceh.2021.11.010 - Arvind M, Verma A, Shalimar, Sardana V, et al. (Phenome India). Lancet Reg Health Southeast Asia 2026;45:100723. 7,764 Indian adults analysed of 10,267 screened, 27 cities, 37 CSIR laboratories — a workplace cohort, not a random sample. Age-adjusted 38.9% (95% CI 37.2–40.6); crude 47.8%.
https://doi.org/10.1016/j.lansea.2026.100723 - Desai GS, Hajare S, Ghorpade S, Hajare S. Cureus 2025;17(9):e92747. 688 medical students, Belagavi, south India; mean age 20.5; no significant alcohol intake; 23.1% with liver fat on FibroScan (CAP ≥238 dB/m). Published September 2025.
https://doi.org/10.7759/cureus.92747 - Kumar A, Panda JK, Mohan V, Misra A, et al. (DiaFib-Liver). Lancet Reg Health Southeast Asia 2026;47:100753. 9,202 Indian adults with type 2 diabetes, asymptomatic for liver disease, multicentre, vibration-controlled transient elastography, measured January–July 2024; mean age 53.3 (SD 11.8), 61% male. Each figure with its own denominator: significant fibrosis ≥8 kPa 26% (2,433/9,202); advanced ≥10 kPa 14% (1,289/9,202); probable cirrhosis ≥15 kPa 5% (491/9,202); non-obese BMI <25 19% (752/3,996); no steatosis but significant fibrosis 13% (370/2,847), of whom 4% (107/2,847) at probable cirrhosis.
https://doi.org/10.1016/j.lansea.2026.100753 - Singhai A et al. Indian J Med Res 2026;164(1):72–80. Pooled 18 studies, 81,364 Indian adults with type 2 diabetes, studies from 2000–2025: 56.9% (95% CI 39.1–74.8).
https://doi.org/10.25259/IJMR_2480_2025 - Bhagat N, De A, Duseja A, et al. Indian J Med Res 2026;163(4):477–485. Open-label randomised trial, 66 non-obese (BMI <25) Indian adults with MASLD and ALT >50, PGIMER Chandigarh. Median CAP fall 14 dB/m with lifestyle alone vs 24 dB/m with the drug added, p = 0.52. The drug arm was superior on three secondary outcomes: HOMA-IR (p = 0.03), triglycerides (p = 0.006), ALT (p = 0.04).
https://doi.org/10.25259/IJMR_2953_2025 - Tiwari AK, Singh G, Kumar V, et al. Indian J Med Res 2026;163(5):598–605. Three-arm randomised trial, 150 non-diabetic Indians aged 19–55, BHU Varanasi, 24 weeks. Saroglitazar and vitamin E were no better than lifestyle alone on liver stiffness or fibrosis score. (39% vs 19% reached a ≥2 kPa fall, but that comparison was not tested statistically.)
https://doi.org/10.25259/IJMR_2511_2025 - Raj PS, John R, Kapoor N, et al. (CMC Vellore). Lean MASLD. Best Pract Res Clin Endocrinol Metab 2026;40(4):102107. Review by Indian authors; the 10–20% lean share quoted inside it is a global figure, not an Indian measurement.
https://doi.org/10.1016/j.beem.2026.102107 - Indian National Association for Study of the Liver (INASL). Adoption of the MASLD nomenclature. J Clin Exp Hepatol 2025;15(5):102590. The Indian guidance in force is INASL 2023, read under the MASLD name.
https://doi.org/10.1016/j.jceh.2025.102590